GLP-1 medications have gained national attention for its impact on weight loss over the last year. And as demand continues to surge, employers face a tough dilemma: do the potential benefits for weight loss, including potential direct and indirect savings on obesity-related health issues, justify the high cost of covering weight loss medications? Hear Dr. Linda Anegawa, Chief of Medicine at Noom, and award-winning, board-certified physician in Obesity Medicine and Internal Medicine, share her perspective on this timely topic and how Noom is enabling employers to responsibly address it.

Sponsored by Noom

In-person session offerings are on a first-come, first-served basis.

To view all event accessibility & accommodations details visit here.

If a speaker has provided session materials, please visit https://presentations.shrm.org